|
Outcome and Vesting Level
|
||
Portion of the Award
|
Measure and Outcome
|
% of maximum
|
% of award
|
30%
|
Adjusted Free Cash Flow -
For the three years ending 31 December 2023, the Company achieved
Adjusted Free Cash Flow calculated in accordance with the
principles for the measure of £9.81bn, which is above the
revised amount of £6.54bn required for maximum
vesting.
Adjustments to the original target and vesting schedule were set
out in detail in the 2022 Annual Report.
|
100
|
30.00
|
30%
|
Total Shareholder Return -
For the three-year period the Company's Total Shareholder Return
ranked 9th, which is below the threshold vesting level against a
comparator group of 10 global pharmaceutical companies including
GSK.
|
0
|
0.00
|
20%
|
Innovation Sales - For the
three-year period, the Company achieved revenues from new products
calculated in accordance with the principles for the measure of
£18.651bn, which is slightly below the level of £18.667bn
required for 100% vesting. The threshold vesting level was
£15.273bn.
|
99.77
|
19.95
|
20%
|
Pipeline Progress - measure is equally weighted
between:
-
Pivotal trial starts
-
Major regulatory approvals
|
100
100
|
10.00
10.00
|
|
Total vesting for 2021 award
Lapsed
|
69.95
30.05
|
69.95
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Emma Walmsley
|
|||
b)
|
Position/status
|
Chief Executive Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan. These shares
are now subject to a two-year hold.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
441,309
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Diana Conrad
|
|||
b)
|
Position/status
|
Chief People Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
89,414
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Diana Conrad
|
|||
b)
|
Position/status
|
Chief People Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
47,864
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
James Ford
|
|||
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
139,077
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
James Ford
|
|||
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
65,367
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally Jackson
|
|||
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
52,746
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally Jackson
|
|||
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
24,791
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dylan Jackson
|
|||
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021,
2022 and 2023 under the Company's 2017 Performance Share
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
7,642
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dylan Jackson
|
|||
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021, 2022 and 2023 under the Company's 2017
Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
3,592
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Luke Miels
|
|||
b)
|
Position/status
|
Chief Commercial Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
195,810
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Luke Miels
|
|||
b)
|
Position/status
|
Chief Commercial Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
13,864
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Shobie Ramakrishnan
|
|||
b)
|
Position/status
|
Chief Digital and Technology Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$0.00
|
5,383
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Shobie Ramakrishnan
|
|||
b)
|
Position/status
|
Chief Digital and Technology Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$41.84
|
2,894
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
David Redfern
|
|||
b)
|
Position/status
|
President, Corporate Development
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
161,385
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
David Redfern
|
|||
b)
|
Position/status
|
President, Corporate Development
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
75,851
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Regis Simard
|
|||
b)
|
Position/status
|
President, Global Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
133,024
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Regis Simard
|
|||
b)
|
Position/status
|
President, Global Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
62,522
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Phil Thomson
|
|||
b)
|
Position/status
|
President, Global Affairs
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
73,728
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Phil Thomson
|
|||
b)
|
Position/status
|
President, Global Affairs
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
34,653
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Deborah Waterhouse
|
|||
b)
|
Position/status
|
CEO, ViiV Healthcare and President, GSK Global Health
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
94,120
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Deborah Waterhouse
|
|||
b)
|
Position/status
|
CEO, ViiV Healthcare and President, GSK Global Health
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
44,237
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Tony Wood
|
|||
b)
|
Position/status
|
Chief Scientific Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
24,473
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Tony Wood
|
|||
b)
|
Position/status
|
Chief Scientific Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
11,503
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Victoria Whyte
|
|||
b)
|
Position/status
|
Company Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2021
under the Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
9,456
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Victoria Whyte
|
|||
b)
|
Position/status
|
Company Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2021 under the Company's 2017 Performance
Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.6055
|
4,445
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Hal Barron
|
|||
b)
|
Position/status
|
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$0.00
|
107,377
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Hal Barron
|
|||
b)
|
Position/status
|
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$41.84
|
57,716
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-02-09
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: February
13, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|